In fiscal year 2025, Prestige BioPharma Limited (950210) reported revenue of 10 million KRW.
Income Statement
| Year | Revenue | Op Profit | Net Income | Source |
|---|---|---|---|---|
| 2025 | 10 million KRW | -48 million KRW | 3 million KRW | [source] |
| 2024 | 517,114 KRW | -47 million KRW | -41 million KRW | [source] |
| 2023 | 122,410 KRW | -53 million KRW | -2 million KRW | [source] |
| 2022 | — | -49 million KRW | -176 million KRW | [source] |
| 2021 | — | -16 million KRW | -7 million KRW | [source] |
Balance Sheet
| Year | Total Assets | Total Liabilities | Total Equity | Source |
|---|---|---|---|---|
| 2025 | 503 million KRW | 63 million KRW | 439 million KRW | [source] |
| 2024 | 410 million KRW | 26 million KRW | 384 million KRW | [source] |
| 2023 | 421 million KRW | 28 million KRW | 392 million KRW | [source] |
| 2022 | 400 million KRW | 31 million KRW | 370 million KRW | [source] |
| 2021 | 536 million KRW | 25 million KRW | 510 million KRW | [source] |
This company has no revenue account in the DART financial statements. Industry-specific accounts such as insurance or interest income are not converted to revenue.